RSV Season 2026: Why States Are Extending Infant Immunization Windows
Respiratory syncytial virus (RSV) is behaving unexpectedly this year. While the virus typically peaks in winter and winds down by early spring, 2026 has seen a surge that’s lingering much longer than usual. In response, health departments across most U.S. States are extending the window for RSV immunizations for eligible infants and toddlers through the end of April.
For parents and caregivers, this shift means that the window to protect the youngest and most vulnerable children has widened to combat an unusually persistent season.
The Data Behind the Late Surge
The decision to extend immunization periods isn’t arbitrary; it’s driven by a significant spike in test positivity rates. According to federal data, the test positivity rate for RSV during the third week of March hit 7.5%. To put that in perspective, the rate during the same period last year was 5% and even lower in the years preceding that.
Dr. Susan Kansagra, chief medical officer for the Association of State and Territorial Health Officials, notes that many areas are seeing hospitalizations and emergency department visits linger well into the spring. Because of this ongoing transmission, health departments are recommending that providers continue the administration of monoclonal antibodies into April to reduce the risk of severe illness.
Why RSV is a Critical Concern for Infants
While RSV often feels like a common cold for healthy adults, it’s a different story for infants. It remains the leading cause of infant hospitalization in the United States. CDC data indicates that two to three out of every 100 infants younger than three months are hospitalized with RSV annually. This season alone, tens of thousands of children have already required hospitalization.
To mitigate these risks, the American Academy of Pediatrics recommends immunization with monoclonal antibodies, which can significantly decrease the likelihood of severe infection, and hospitalization.
Current Regulatory Scrutiny of RSV Therapies
While medical societies emphasize the life-saving nature of these preventatives, the regulatory landscape is currently in flux. The U.S. FDA has launched fresh safety scrutiny of approved RSV treatments for infants, specifically targeting Beyfortus (developed by Sanofi and AstraZeneca) and Enflonsia (developed by Merck).
This review is taking place under U.S. Health Secretary Robert F. Kennedy Jr., who has questioned whether the potential risks of various pharmaceutical products have been sufficiently studied. This scrutiny follows inquiries initiated by FDA officials, including senior adviser Tracy Beth Hoeg, as well as concerns raised by vaccine skeptics regarding potential risks, such as seizures.
Key Takeaways for Parents
- Extended Deadline: Most states have moved the RSV immunization deadline from the end of March to the end of April.
- Higher Prevalence: Test positivity rates in March were 7.5%, significantly higher than the 5% seen last year.
- High Risk: RSV is the primary cause of infant hospitalizations; 2-3% of infants under three months are hospitalized annually.
- Preventative Care: Monoclonal antibodies are the recommended tool for preventing severe infection in eligible infants.
Frequently Asked Questions
What are monoclonal antibodies for RSV?
Unlike traditional vaccines that teach the body to produce its own antibodies, monoclonal antibodies provide “passive immunity” by giving the infant ready-made antibodies to fight the virus immediately.
Who is eligible for the extended immunization window?
The extension primarily affects eligible infants and toddlers who have not yet received their RSV preventative treatment for the current season.
Why is the FDA reviewing these treatments now?
The review is part of a broader effort by Health Secretary Robert F. Kennedy Jr. To re-examine routine childhood immunizations and ensure that all pharmaceutical risks have been properly studied.
As the 2026 RSV season continues to defy typical patterns, parents are encouraged to consult their pediatricians to determine if their child is eligible for immunization before the end-of-April window closes.